- AstraZeneca (AZN -0.3%) biologics R&D unit MedImmune and Incyte (INSY -6%) collaborate on a Phase 1/2 clinical trial to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor MEDI4736 in combination with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
- MEDI4736 blocks the signals that help tumors avoid detection by the immune system while INCB24360 enhances immune cells' ability to fight the tumor.
- The two firms collaborate on a non-exclusive basis. They expect the Phase 1 trial to establish a recommended dose regimen and Phase 2 to assess the safety and efficacy of the combination. Further development of the combo is contingent on the results of the trials.
Incyte and MedImmune collaborate on cancer immunotherapies
From other sites
Video at CNBC.com (Feb 11, 2015)
at CNBC.com (Feb 5, 2015)
at CNBC.com (Jan 14, 2015)
at CNBC.com (Jan 8, 2015)
at CNBC.com (Dec 29, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs